marion merrell dow the us pharmaceuticals group is looking for a substantial pan-european acquisition according to senior company executives the aim of any acquisition would be to increase sales in its european prescription drugs and over-the-counter non-prescription businesses the group generates about 30 per cent of its turnover outside the us and about 23 per cent in europe marion merrell dow would also like to acquire manufacturing capacity says mr ronald irwin chairman and managing director of marion merrell dow's uk operations the group's british production site was acquired by procter gamble the us consumer products group when it bought richardson-vicks in 1986 marion merrell dow now uses contract manufacturers mr irwin says the group has considerable cash reserves to make an acquisition cash and short-term investments at the end of last year were dollars 414 m however another route available to the company might be a merger merchant bankers are known to have approached at least one leading british pharmaceuticals group suggesting such a deal any european acquisition would compliment marion merrell dow's purchase last year of the berlin-based pharmaceuticals group henning in 1991, the us group attempted to acquire nicholas labs the european otc business of the us company sara lee which was eventually bought by roche of switzerland for dollars 790 m the us group needs to drive earnings through acquisitions us patents for its two leading products cardizem and seldane are due to expire within the next two years sales of nicoderm its nicotine patch together with those of nicorette nicotine gum increased 122 per cent last year however they are expected to slow this year